Pharming Group

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Pharming Group and other ETFs, options, and stocks.

About PHAR

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema.

CEO

Sijmen de Vries

CEOSijmen de Vries

Employees

—

Employees—

Headquarters

Leiden, Zuid-Holland

HeadquartersLeiden, Zuid-Holland

Founded

1988

Founded1988

Employees

—

Employees—

PHAR Key Statistics

Market cap

825.00M

Market cap825.00M

Price-Earnings ratio

26.42

Price-Earnings ratio26.42

Dividend yield

—

Dividend yield—

Average volume

6.36K

Average volume6.36K

High today

$13.25

High today$13.25

Low today

$11.76

Low today$11.76

Open price

$12.35

Open price$12.35

Volume

4.64K

Volume4.64K

52 Week high

$13.25

52 Week high$13.25

52 Week low

$6.10

52 Week low$6.10

PHAR Earnings

-$0.00

$0.01

$0.02

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 16, Pre-Market

ActualExpected Mar 16, Pre-Market

Pharming Group

Why Robinhood?

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. Show more

PHAR Key Statistics

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema.